医学
生物仿制药
英夫利昔单抗
炎症性肠病
溃疡性结肠炎
危险系数
阿达木单抗
内科学
置信区间
比例危险模型
医疗保健
逻辑回归
重症监护医学
疾病
克罗恩病
回顾性队列研究
梅德林
依那西普
优势比
成果研究
硫嘌呤甲基转移酶
原发性硬化性胆管炎
年轻人
不利影响
疾病严重程度
临床试验
队列研究
生物制剂
急诊医学
作者
Cristiano S Moura,Albert Etingin,Luck Lukusa,Harminder Singh,Neeraj Narula,Laura E Targownik,Yvette Leung,Petros Zezos,Beata Polewiczowska-Nowak,Waqqas Afif,Sasha Bernatsky
标识
DOI:10.3748/wjg.v32.i9.114580
摘要
BACKGROUND: Biologic therapies, including anti-tumor necrosis factor agents, have significantly improved the management of inflammatory bowel disease (IBD). However, their high cost can limit patient access. Biosimilars are a more affordable option than originator biologics and offer potential for improved accessibility, though real-world evidence comparing their effectiveness remains limited. AIM: To describe real-world, comparative outcomes of IBD patients taking biologics and biosimilars, focusing on remission and healthcare use. METHODS: We used data from a multicenter registry-based cohort, which includes participants from six Canadian IBD clinical centers. Adults with ulcerative colitis or Crohn's disease who initiated biosimilar, or originator formulations of infliximab or adalimumab were included. The primary outcome was clinical remission; secondary outcomes included hospitalizations and emergency department (ED) visits. Kaplan-Meier survival analyses and multivariable Cox regression models were used to assess time to these outcomes, adjusting for disease activity, treatment history, and demographic characteristics. RESULTS: A total of 258 individuals were analyzed (192 biosimilar initiators and 66 originator users). The median time to remission was similar between biosimilars (12.2 months) and originators (12.8 months). We did not detect difference in the likelihood of achieving remission when comparing biosimilar and originator treatments (adjusted hazard ratio: 1.49; 95% confidence interval: 0.96-2.32). Hospitalization and ED visit rates were also comparable. Corticosteroid use and prior hospitalizations were associated with increased hospitalization risk. CONCLUSION: This study suggests biosimilars and originators have similar remission, ED visits, and hospitalization in IBD. This reinforces confidence in their equivalence, improving access while supporting healthcare system sustainability.
科研通智能强力驱动
Strongly Powered by AbleSci AI